Eli Lil­ly pulls mil­lions in Twit­ter ad­ver­tis­ing af­ter fake ac­count de­ba­cle — re­port

3 years ago
Pharma
Marketing

Af­ter CRL, drug de­vel­op­er duo re­sub­mits its ex­per­i­men­tal drug to the FDA, look­ing to com­pete with Fab­razyme

3 years ago
R&D
FDA+

With new up­date in hand, In­tel­lia CEO now claims one-time HAE gene edit­ing treat­ment 'may be a func­tion­al cure'

3 years ago
R&D
Cell/Gene Tx

Io­n­is part­ners up with Metageno­mi on drug dis­cov­ery pact, shelling out $80M up­front

3 years ago
Deals
R&D

Aim­ing at main­stream mar­kets, ra­dio­phar­ma­ceu­ti­cal part­ners en­gi­neer $260M cash deal

3 years ago
Deals

RA Cap­i­tal jumps aboard nine-fig­ure round for the en­docrine biotech co-found­ed by Hu­ma­log in­ven­tor

3 years ago
Financing

Stoke teas­es ear­ly ef­fi­ca­cy da­ta for pos­si­ble PhI­II dose in lead Dravet syn­drome pro­gram

3 years ago
R&D

Up­dat­ed: Roche hits the brakes on Alzheimer's tri­als af­ter res­ur­rect­ed drug flunks PhI­II

3 years ago
R&D

Roivant cuts 12% of staff in cost-sav­ing move

3 years ago
People
Pharma

Bio­gen, Seagen lock in CEOs; 2022 so far — by the num­bers; Phar­ma on Twit­ter; Wave of biotech down­siz­ing ; and more

3 years ago
Weekly

Seagen's high­est sell­ing drug snags a la­bel ex­pan­sion for pe­di­atric can­cer pa­tients

3 years ago
Pharma
FDA+

IRA im­pact: As­traZeneca and Mer­ck CEOs warn of on­col­o­gy drug de­vel­op­ment shifts

3 years ago
R&D

Phar­ma and health­care ads miss the mark on re­al­is­tic por­tray­als of women — study

3 years ago
Pharma
Marketing

As­traZeneca's can­cer com­bo wins sec­ond nod in one month, this time in lung can­cer

3 years ago
Pharma
FDA+

Phar­ma-backed char­i­ty sues HHS to help pay for se­niors' pricey can­cer drugs

3 years ago
Pharma
Law

FTC calls out Jazz Phar­ma's abuse of FDA Or­ange Book list­ing process

3 years ago
Law

Nor­we­gian biotech con­cludes 's­trate­gic' re­view with a re­verse merg­er

3 years ago
Deals

Fol­low­ing se­cre­tive Ab­Cellera pact, Mod­er­na picks up an­oth­er an­ti­body dis­cov­ery deal via Har­bour Bio­Med

3 years ago
Deals
R&D

Lay­off trend con­tin­ues as three more biotechs an­nounce re­duc­tions in staff

3 years ago
People
R&D

Elon Musk's pay-for-play Twit­ter sows chaos as fake Eli Lil­ly ac­count pro­claims in­sulin is free

3 years ago
People
Pharma

GSK pulls an­oth­er can­cer in­di­ca­tion for Ze­ju­la at FDA's re­quest

3 years ago
Pharma

Fourth time's the charm? blue­bird picks up new fi­nance chief; New CEOs here and there

3 years ago
Peer Review

Curis shrinks head­count by 30% as ex­ecs place big­ger hopes on blood can­cer drug

3 years ago
People

Meta­bol­ics biotech se­cures hum­ble Se­ries A from big-name in­vestors

3 years ago
People
Financing
First page Previous page 429430431432433434435 Next page Last page
A service from the Financial Times